Needham Lifts TransMedics Price Target to $174 After Strong Q4 Beat
Needham has increased its price target on TransMedics Group (TMDX) to $174 from $166 and kept a Buy rating after the company reported fourth-quarter 2025 results that outperformed consensus. Revenue and adjusted EPS exceeded estimates, management issued 2026 revenue guidance above expectations, and operational metrics including case volumes and mar…